So Sánh Trình Tự Nucleotide Của 03 Chủng (Chủng Giống Gốc Bv-Msv-021, Bv-Wsv- 031 Và

in southeast Asia", J Virol. 77(5), pg. 3091-8.

37. Y. C. Fan et al. (2012), "Partially neutralizing potency against emerging genotype I virus among children received formalin-inactivated Japanese encephalitis virus vaccine", PLoS Negl Trop Dis. 6(9), pg. e1834.

38. P. E. Nasveld et al. (2010), "Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity", Hum Vaccin. 6(11), pg. 906-14.

39. 39. M. Ferguson et al. (2008), "Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines--report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies", Biologicals. 36(2), pg. 111-6.

40. I. Kurane and T. Takasaki (2000), "Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains", Vaccine. 18 Suppl 2, pg. 33-5.

41. W. R. Shyu et al. (1997), "Assessment of neutralizing antibodies elicited by a vaccine (Nakayama) strain of Japanese encephalitis virus in Taiwan", Epidemiol Infect. 119(1), pg. 79-83.

42. Vaccine Schedule (2014), Japanese encephalitis vaccines. Available at: http://archive-in.com/page/2155428/2013-05-24

/http://www.vaccineschedule.in/Japanese.aspx.

43. Hội đồng Dược điển Việt Nam (2017), Dược điển Việt Nam V: Vắc xin Viêm não Nhật Bản, Bộ Y tế, Hà Nội.

Có thể bạn quan tâm!

Xem toàn bộ 178 trang tài liệu này.

44. K. L. Schiøler, M. Samuel and K. L. Wai (2007), "Vaccines for preventing Japanese encephalitis", Cochrane Database Syst Rev. 2007(3), pg. Cd004263.

45. E. Tauber et al. (2007), "Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial", Lancet. 370(9602), pg. 1847-53.

46. K. W. Yun et al. (2015), "Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis

vaccine in children: a phase III, multicenter, double-blinded, randomized trial", BMC Infect Dis. 15, pg. 7.

47. Phan Thị Ngà và các cộng sự. (2010), "Hiệu quả phòng bệnh VNNB bằng vắc xin ở một số tỉnh miền Bắc Việt Nam, 1998-2007", Tạp chí Y học dự phòng. 20(5), tr. 29-35.

48. Nguyễn Thu Yến (2002), "Hiệu quả phòng bệnh VNNB ở huyện Gia Lương, tỉnh Bắc Ninh sau 7 năm (1993-1999) gây miễn dịch bằng vắc xin của Viện VSDTTƯ sản xuất", Tạp chí Y học. 5(423), tr. 76-78.

49. L. P. Do et al. (2015), "Molecular epidemiology of Japanese encephalitis in northern Vietnam, 1964-2011: genotype replacement", Virol J. 12, pg. 51.

50. J. Schuh et al. (2014), "Dynamics of the emergence and establishment of a newly dominant genotype of Japanese encephalitis virus throughout Asia", J Virol. 88(8), pg. 4522-32.

51. 51. S. Y. Wang et al. (2015), "Comparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: A systematic review and meta-analysis", Hum Vaccin Immunother. 11(6), pg. 1418-25.

52. J. Wang et al. (2015), "The A66G back mutation in NS2A of JEV SA14-14-2 strain contributes to production of NS1' protein and the secreted NS1' can be used for diagnostic biomarker for virulent virus infection", Infect Genet Evol. 36, pg. 116-125.

53. E. O. Erra and A. Kantele (2015), "The Vero cell-derived, inactivated, SA14- 14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis", Expert Rev Vaccines. 14(9), pg. 1167-79.

54. G. D. Gromowski, C. Y. Firestone and S. S. Whitehead (2015), "Genetic Determinants of Japanese Encephalitis Virus Vaccine Strain SA14-14-2 That Govern Attenuation of Virulence in Mice", J Virol. 89(12), pg. 6328-37.

55. S. I. Yun et al. (2016), "Comparison of the live-attenuated Japanese encephalitis vaccine SA14-14-2 strain with its pre-attenuated virulent parent SA14 strain: similarities and differences in vitro and in vivo", J Gen Virol. 97(10), pg. 2575-2591.

56. D. S. Kim et al. (2014), "A randomized study of the immunogenicity and

safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea", Hum Vaccin Immunother. 10(9), pg. 2656-63.

57. A. Kaltenböck et al. (2010), "Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age", Vaccine. 28(3), pg. 834-9.

58. S. Lee et al. (2016), "Establishment of the 3rd national standard for lot release testing of the Japanese encephalitis vaccine (Nakayama-NIH strain) in Korea", Hum Vaccin Immunother. 12(7), pg. 1805-7.

59. S. Kiesslich and A. A. Kamen (2020), "Vero cell upstream bioprocess development for the production of viral vectors and vaccines", Biotechnol Adv. 44, pg. 107608.

60. T. Woolpert et al. (2012), "Immunogenicity of one dose of Vero cell culture- derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine", Vaccine. 30(20), pg. 3090-6.

61. T. Miura (1970), "A new method for a potency test of Japanese encephalitis vaccine. Direct challenge method on suckling mice by subcutaneous inoculation", Bull World Health Organ. 43(4), pg. 553-7.

62. B. Singh and W. M. Hammon (1971), "Studies on Japanese B encephalitis virus vaccines from tissue culture. XI. Immune mechanism and evaluation of the mouse challenge potency test", Appl Microbiol. 21(4), pg. 743-8.

63. S. Payne (2017), Methods to Study Viruses, Viruses. 2017:37-52. doi: 10.1016/B978-0-12-803109-4.00004-0. Epub 2017 Sep 1.

64. Arran Folly et al. (2021), "Temperate conditions restrict Japanese encephalitis virus infection to the mid-gut and prevents systemic dissemination in Culex pipiens mosquitoes", Scientific Reports. 11, pg. 6133.

65. Cheryl Johansen et al. (2002), "Detection and stability of Japanese Encephalitis virus RNA and virus viability in dead infected mosquitoes under different storage conditions", The American journal of tropical medicine and hygiene. 67.

66. Z. G. Yuan et al. (2014), "Culture of Japanese encephalitis virus in bioreactor

and its inactivation and purification", Chinese Journal of Biologicals. 27, pg. 1309-1312.

67. S. Tajima et al. (2010), "A single mutation in the Japanese encephalitis virus E protein (S123R) increases its growth rate in mouse neuroblastoma cells and its pathogenicity in mice", Virology. 396(2), pg. 298-304.

68. S. Tajima et al. (2015), "In vitro growth, pathogenicity and serological characteristics of the Japanese encephalitis virus genotype V Muar strain", J Gen Virol. 96(9), pg. 2661-2669.

69. W. L. Deng et al. (2014), "Fine mapping of a linear epitope on EDIII of Japanese encephalitis virus using a novel neutralizing monoclonal antibody", Virus Res. 179, pg. 133-9.

70. V. C. Luca et al. (2012), "Crystal structure of the Japanese encephalitis virus envelope protein", J Virol. 86(4), pg. 2337-46.

71. X. Zhang et al. (2017), "Structures and Functions of the Envelope Glycoprotein in Flavivirus Infections", Viruses. 9(11).

72. M. Nain et al. (2017), "GRP78 Is an Important Host Factor for Japanese Encephalitis Virus Entry and Replication in Mammalian Cells", J Virol. 91(6).

73. E. Fernandez et al. (2018), "Mouse and Human Monoclonal Antibodies Protect against Infection by Multiple Genotypes of Japanese Encephalitis Virus", mBio. 9(1).

74. A. J. Schuh et al. (2013), "Genetic diversity of Japanese encephalitis virus isolates obtained from the Indonesian archipelago between 1974 and 1987", Vector Borne Zoonotic Dis. 13(7), pg. 479-88.

75. M. de Wispelaere et al. (2015), "A Single Amino Acid Substitution in the M Protein Attenuates Japanese Encephalitis Virus in Mammalian Hosts", J Virol. 90(5), pg. 2676-89.

76. P. A. Desingu et al. (2017), "First Complete Genome Sequence of Genotype III Japanese Encephalitis Virus Isolated from a Stillborn Piglet in India", Genome Announc. 5(3).

77. B. Lu et al. (2017), "Full-Length Genome Sequence of Japanese Encephalitis Virus Strain FC792, Isolated from Guangxi, China", Genome Announc. 5(48).

78. X. Gao et al. (2019), "Changing Geographic Distribution of Japanese Encephalitis Virus Genotypes, 1935-2017", Vector Borne Zoonotic Dis. 19(1), pg. 35-44.

79. A. R. S. Oliveira et al. (2018), "Assessment of data on vector and host competence for Japanese encephalitis virus: A systematic review of the literature", Prev Vet Med. 154, pg. 71-89.

80. A. M. Samy et al. (2018), "Mapping the potential distributions of etiological agent, vectors, and reservoirs of Japanese Encephalitis in Asia and Australia", Acta Trop. 188, pg. 108-117.

81. N. T. Yen et al. (2010), "Surveillance for Japanese encephalitis in Vietnam, 1998-2007", Am J Trop Med Hyg. 83(4), pg. 816-9.

82. N. Han et al. (2014), "Comparison of genotypes I and III in Japanese encephalitis virus reveals distinct differences in their genetic and host diversity", J Virol. 88(19), pg. 11469-79.

83. Ryusei Kuwata et al. (2013), "Surveillance of Japanese encephalitis virus infection in mosquitoes in Vietnam from 2006 to 2008", The American journal of tropical medicine and hygiene. 88(4), pg. 681-688.

84. U. Roy (2020), "Insight into the structures of Interleukin-18 systems", Comput Biol Chem. 88, pg. 107353.

85. J. J. Chu, P. W. Leong and M. L. Ng (2005), "Characterization of plasma membrane-associated proteins from Aedes albopictus mosquito (C6/36) cells that mediate West Nile virus binding and infection", Virology. 339(2), pg. 249-60.

86. EMA Guideline on the Quality (2018), Non-Clinical and Clinical Aspects of Gene Therapy Medicinal Products (March 2018).

87. EudraLex The Rules Governing Medicinal Products in the European Union (2018), EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 2 Manufacture of Biological Medicinal Substances and Products for Human Use (June 2018).

88. P. Chanthavanich et al. (2018), "Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children", Hum Vaccin Immunother. 14(4), pg. 900-905

89. T. Jelinek et al. (2018), "Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO(®), JESPECT(®)) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 study", Travel Med Infect Dis. 22, pg. 18-24.

90. E. O. Erra et al. (2012), "A single dose of vero cell-derived Japanese encephalitis (JE) vaccine (Ixiaro) effectively boosts immunity in travelers primed with mouse brain-derived JE vaccines", Clin Infect Dis. 55(6), pg. 825-34.

91. K. W. Yun et al. (2018), "Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE- VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine", Vaccine. 36(11), pg. 1398-1404.

92. N. Takeshita et al. (2014), "Immunogenicity of single-dose Vero cell-derived Japanese encephalitis vaccine in Japanese adults", J Infect Chemother. 20(4), pg. 238-42.

93. K. Okada et al. (2012), "Safety and immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (Inactivated) (JEBIK(®)V) in children", Vaccine. 30(41), pg. 5967-72.

94. B. W. Johnson et al. (2016), "Differential Diagnosis of Japanese Encephalitis Virus Infections with the Inbios JE Detect™ and DEN Detect™ MAC-ELISA Kits", Am J Trop Med Hyg. 94(4), pg. 820-828

95. S. Robinson et al. (2010), "Evaluation of three commercially available Japanese encephalitis virus IgM enzyme-linked immunosorbent assays", Am J Trop Med Hyg. 83(5), pg. 1146-55.

96. H. J. Seo et al. (2013), "Molecular detection and genotyping of Japanese encephalitis virus in mosquitoes during a 2010 outbreak in the Republic of Korea", PLoS One. 8(2), pg. e55165.

97. Nan Shao et al. (2018), "TaqMan Real-time RT-PCR Assay for Detecting and Differentiating Japanese Encephalitis Virus", Biomedical and Environmental Sciences. 31(3), pg. 208-214.

98. Indian Pharmacopoeia 2018, pg 3645.

PHỤ LỤC

Phụ lục 1. SO SÁNH TRÌNH TỰ NUCLEOTIDE CỦA 03 CHỦNG (CHỦNG GIỐNG GỐC BV-MSV-021, BV-WSV- 031 VÀ CHỦNG THAM CHIẾU Beijing-Kanonji)

....|....|....|....| ....|....|....|....| ....|....|

10 20 30 40 50

BV-MSV-021 TTCAACTGTC TGGGAATGGG CAATCGTGAC TTCATAGAAG GAGCCAGTGG

BV-WSV-031 TTCAACTGTC TGGGAATGGG CAATCGTGAC TTCATAGAAG GAGCCAGTGG

Beijing-Ka TTCAACTGTC TGGGAATGGG CAATCGTGAC TTCATAGAAG GAGCCAGTGG

....|....|....|....| ....|....|....|....| ....|....|

60 70 80 90 100

BV-MSV-021 AGCCACTTGG GTGGACTTGG TGCTAGAAGG AGACAGCTGC TTGACAATCA

BV-WSV-031 AGCCACTTGG GTGGACTTGG TGCTAGAAGG AGACAGCTGC TTGACAATCA

Beijing-Ka AGCCACTTGG GTGGACTTGG TGCTAGAAGG AGACAGCTGC TTGACAATCA

....|....|....|....| ....|....|....|....| ....|....|

110 120 130 140 150

BV-MSV-021 TGGCAAACGA CAAACCAACA TTGGACGTCC GCATGATCAA CATCGAAGCT

BV-WSV-031 TGGCAAACGA CAAACCAACA TTGGACGTCC GCATGATCAA CATCGAAGCT

Beijing-Ka TGGCAAACGA CAAACCAACA TTGGACGTCC GCATGATCAA CATCGAAGCT

....|....|....|....| ....|....|....|....| ....|....|

160 170 180 190 200

BV-MSV-021 AGCCAACTTG CTGAGGTCAG AAGTTACTGC TATCATGCTT CAGTCACTGA

BV-WSV-031 AGCCAACTTG CTGAGGTCAG AAGTTACTGC TATCATGCTT CAGTCACTGA

Beijing-Ka AGCCAACTTG CTGAGGTCAG AAGTTACTGC TATCATGCTT CAGTCACTGA

....|....|....|....| ....|....|....|....| ....|....|

210 220 230 240 250

BV-MSV-021 CATCTCGACG GTGGCTCGGT GCCCCACGAC TGGAGAAGCC CACAACGAGA

BV-WSV-031 CATCTCGACG GTGGCTCGGT GCCCCACGAC TGGAGAAGCC CACAACGAGA

Beijing-Ka CATCTCGACG GTGGCTCGGT GCCCCACGAC TGGAGAAGCC CACAACGAGA

....|....|....|....| ....|....|....|....| ....|....|

260 270 280 290 300

BV-MSV-021 AGCGAGCTGA TAGTAGCTAT GTGTGCAAAC AAGGCTTCAC TGATCGTGGG

BV-WSV-031 AGCGAGCTGA TAGTAGCTAT GTGTGCAAAC AAGGCTTCAC TGATCGTGGG

Beijing-Ka AGCGAGCTGA TAGTAGCTAT GTGTGCAAAC AAGGCTTCAC TGATCGTGGG

310 320 330 340 350

BV-MSV-021 TGGGGCAACG GATGTGGACT TTTCGGGAAG GGAAGTATTG ACACATGTGC

BV-WSV-031 TGGGGCAACG GATGTGGACT TTTCGGGAAG GGAAGTATTG ACACATGTGC

Beijing-Ka TGGGGCAACG GATGTGGACT TTTCGGGAAG GGAAGTATTG ACACATGTGC

....|....|....|....| ....|....|....|....| ....|....|

360 370 380 390 400

BV-MSV-021 AAAATTCTCC TGCACCAGGA AAGCGATTGG GAGAACAATC CAGCCAGAAA

BV-WSV-031 AAAATTCTCC TGCACCAGGA AAGCGATTGG GAGAACAATC CAGCCAGAAA

Beijing-Ka AAAATTCTCC TGCACCAGGA AAGCGATTGG GAGAACAATC CAGCCAGAAA

....|....|....|....| ....|....|....|....| ....|....|

410 420 430 440 450

BV-MSV-021 ACATCAAATA CGAAGTTGGC ATTTTTGTGC ATGGAACCAC CACTTCGGAA

BV-WSV-031 ACATCAAATA CGAAGTTGGC ATTTTTGTGC ATGGAACCAC CACTTCGGAA

Beijing-Ka ACATCAAATA CGAAGTTGGC ATTTTTGTGC ATGGAACCAC CACTTCGGAA

....|....|....|....| ....|....|....|....| ....|....|

460 470 480 490 500

BV-MSV-021 AACCATGGGA ATTATTCAGC GCAAGTTGGG GCGTCCCAGG CGGCAAAGTT

BV-WSV-031 AACCATGGGA ATTATTCAGC GCAAGTTGGG GCGTCCCAGG CGGCAAAGTT

Beijing-Ka AACCATGGGA ATTATTCAGC GCAAGTTGGG GCGTCCCAGG CGGCAAAGTT

....|....|....|....| ....|....|....|....|....|....|

510 520 530 540 550

BV-MSV-021 TACAGTAACA CCTAATGCTC CTTCGATAAC CCTCAAACTT GGTGACTACG

BV-WSV-031 TACAGTAACA CCTAATGCTC CTTCGATAAC CCTCAAACTT GGTGACTACG

Beijing-Ka TACAGTAACA CCTAATGCTC CTTCGATAAC CCTCAAACTT GGTGACTACG

....|....| ....|....|....|....| ....|....| ....|....|

560 570 580 590 600

BV-MSV-021 GAGAAGTCAC ACTGGACTGT GAGCCAAGGA GTGGACTAAA CACTGAAGCG

BV-WSV-031 GAGAAGTCAC ACTGGACTGT GAGCCAAGGA GTGGACTAAA CACTGAAGCG

Beijing-Ka GAGAAGTCAC ACTGGACTGT GAGCCAAGGA GTGGACTAAA CACTGAAGCG

....|....| ....|....|....|....| ....|....|....|....|

610 620 630 640 650

BV-MSV-021 TTTTACGTCA TGACCGTGGG GTCAAAGTCA TTTTTGGTCC ATAGGGAATG

BV-WSV-031 TTTTACGTCA TGACCGTGGG GTCAAAGTCA TTTTTGGTCC ATAGGGAATG

Beijing-Ka TTTTACGTCA TGACCGTGGG GTCAAAGTCA TTTTTGGTCC ATAGGGAATG